However, resistance to crizotinib due to a secondary ALK kinase domain mutation occurred.5, 9 The authors consequently suggested the necessity of consolidation therapy using cytotoxic agents to achieve long-term remission.5 Allogeneic HCT is also a tolerable and curative option after crizotinib therapy, as reported in a case of refractory anaplastic large cell lymphoma.3 Our case achieved CR by crizotinib administration only and then successfully underwent subsequent HCT. Here, ALK is linked to anaplastic large cell lymphoma.